Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Pfizer Inc Announces FDA Approved Lyrica
Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) approved the use of Lyrica (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury. Lyrica received a priority review designation for this new indication from the FDA.
Latest Developments for Pfizer Inc
- Teva Pharmaceutical Industries Ltd and Sun Pharmaceutical Industries Ltd To Pay $2.15 Billion To Settle Pfizer Inc's and Partner Takeda Pharmaceutical Co Ltd's Patent Suit-Reuters
- Pfizer Inc Receives $2.15 Billion Settlement from Teva And Sun For Infringement Of Protonix Patent
- Pfizer Inc Prices $4.0 Billion Debt Offering
- Pfizer Inc Announces Plan For Split-Off Of Zoetis Inc
Latest Key Developments in Pharmaceuticals
- Share this
- Link this
- Digg this
Follow Reuters